The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PTGX | +145.29% | +225.65% | +26.63% | +711% |
| S&P | +18.89% | +78.8% | +12.32% | +214% |
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.
This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $7.44M | -95.6% |
| Gross Profit | $7.06M | -95.8% |
| Gross Margin | 94.94% | -4.7% |
| Market Cap | $5.46B | 137.3% |
| Market Cap / Employee | $41.36M | 126.6% |
| Employees | 132 | 4.8% |
| Net Income | -$44,384.00K | -133.7% |
| EBITDA | -$49,979.00K | -139.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $128.39M | 32.0% |
| Accounts Receivable | $121.00K | -99.9% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.04M | -22.4% |
| Short Term Debt | $2.28M | 347.6% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -18.37% | -68.2% |
| Return On Invested Capital | -21.34% | 24.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$37,119.00K | -25.9% |
| Operating Free Cash Flow | -$36,975.00K | -26.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 9.18 | 63.57 | 77.56 | 104.88 | 521.25% |
| Price to Book | 4.37 | 4.97 | 6.18 | 8.45 | 95.64% |
| Price to Sales | 14.65 | 16.78 | 20.25 | 121.53 | 1959.78% |
| Price to Tangible Book Value | 4.37 | 4.97 | 6.18 | 8.45 | 95.64% |
| Price to Free Cash Flow TTM | 9.08 | 94.62 | 66.49 | 99.72 | 611.15% |
| Enterprise Value to EBITDA | -130.14 | -70.71 | -79.70 | -100.75 | -695.48% |
| Free Cash Flow Yield | 11.0% | 1.1% | 1.5% | 1.0% | -85.94% |
| Return on Equity | 9.0% | 8.6% | 7.8% | -20.2% | -137.10% |
| Total Debt | $11.36M | $11.28M | $10.75M | $10.32M | -5.00% |
No podcast episodes available.
PTGX earnings call for the period ending March 31, 2020.
PTGX earnings call for the period ending March 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
